Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 137 full-time employees. The company went IPO on 2018-09-27. The company designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Ms. Jane Chung est le President de Sutro Biopharma Inc, il a rejoint l'entreprise depuis 2021.
Quelle est la performance du prix de l'action STRO ?
Le prix actuel de STRO est de $38.5, il a 減少 de 2.06% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Sutro Biopharma Inc ?
Sutro Biopharma Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Sutro Biopharma Inc ?
La capitalisation boursière actuelle de Sutro Biopharma Inc est de $637.9M
Est-ce que Sutro Biopharma Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 11 analystes ont établi des notations d'analystes pour Sutro Biopharma Inc, y compris 3 achat fort, 7 achat, 5 maintien, 1 vente et 3 vente forte